These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 23752109

  • 1. Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial.
    Partridge AH, Gelber S, Piccart-Gebhart MJ, Focant F, Scullion M, Holmes E, Winer EP, Gelber RD.
    J Clin Oncol; 2013 Jul 20; 31(21):2692-8. PubMed ID: 23752109
    [Abstract] [Full Text] [Related]

  • 2. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
    Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulos G, Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R, Herceptin Adjuvant (HERA) Trial Study Team.
    Lancet Oncol; 2011 Mar 20; 12(3):236-44. PubMed ID: 21354370
    [Abstract] [Full Text] [Related]

  • 3. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
    Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, Kreienberg R, Camara O, Müller V, du Bois A, Kühn T, Stickeler E, Harbeck N, Höss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G, Loibl S.
    J Clin Oncol; 2011 Sep 01; 29(25):3351-7. PubMed ID: 21788566
    [Abstract] [Full Text] [Related]

  • 4. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).
    Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, Láng I, Wardley A, Lichinitser M, Sanchez RI, Müller V, Dodwell D, Gelber RD, Piccart-Gebhart MJ, Cameron D.
    Lancet Oncol; 2013 Mar 01; 14(3):244-8. PubMed ID: 23414588
    [Abstract] [Full Text] [Related]

  • 5. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?
    Ulas A, Avci N, Kos T, Cubukcu E, Olmez OF, Bulut N, Degirmenci M.
    J BUON; 2015 Mar 01; 20(3):714-22. PubMed ID: 26214622
    [Abstract] [Full Text] [Related]

  • 6. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer.
    Kiess AP, McArthur HL, Mahoney K, Patil S, Morris PG, Ho A, Hudis CA, McCormick B.
    Cancer; 2012 Apr 15; 118(8):1982-8. PubMed ID: 21887681
    [Abstract] [Full Text] [Related]

  • 7. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.
    Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sánchez Rovira P, Piccart-Gebhart MJ, HERA study team.
    Lancet; 2007 Jan 06; 369(9555):29-36. PubMed ID: 17208639
    [Abstract] [Full Text] [Related]

  • 8. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
    Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J.
    J Clin Oncol; 2012 Jul 20; 30(21):2585-92. PubMed ID: 22689807
    [Abstract] [Full Text] [Related]

  • 9. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
    Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, Mariani P, Andre F, Chan A, Lipatov O, Chan S, Wardley A, Greil R, Moore N, Prot S, Pallaud C, Semiglazov V.
    J Clin Oncol; 2013 May 10; 31(14):1719-25. PubMed ID: 23569311
    [Abstract] [Full Text] [Related]

  • 10. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    Baselga J, Perez EA, Pienkowski T, Bell R.
    Oncologist; 2006 May 10; 11 Suppl 1():4-12. PubMed ID: 16971734
    [Abstract] [Full Text] [Related]

  • 11. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
    Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones B, Bell R, Dowsett M, Jackisch C, Herceptin Adjuvant (HERA) Trial Study Team.
    Lancet; 2017 Mar 25; 389(10075):1195-1205. PubMed ID: 28215665
    [Abstract] [Full Text] [Related]

  • 12. Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer.
    Shimizu C, Masuda N, Yoshimura K, Tsuda H, Mano M, Ando M, Tamura K, Fujiwara Y.
    Jpn J Clin Oncol; 2009 Aug 25; 39(8):484-90. PubMed ID: 19477897
    [Abstract] [Full Text] [Related]

  • 13. [Chinese HER2 positive early breast cancer trastuzumab adjuvant therapy: preliminary outcomes].
    Zhang P, Yu SY, Shen ZZ, Song ST, Guan ZZ, Jiao SC, Zheng S, Xu GW, Feng FY.
    Zhonghua Yi Xue Za Zhi; 2012 Dec 18; 92(47):3345-9. PubMed ID: 23328596
    [Abstract] [Full Text] [Related]

  • 14. Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: a large cohort study from clinical practice.
    Bonifazi M, Franchi M, Rossi M, Zambelli A, Moja L, Zambon A, Corrao G, La Vecchia C, Zocchetti C, Negri E.
    Breast; 2014 Oct 18; 23(5):573-8. PubMed ID: 24934637
    [Abstract] [Full Text] [Related]

  • 15. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
    Liberato NL, Marchetti M, Barosi G.
    J Clin Oncol; 2007 Feb 20; 25(6):625-33. PubMed ID: 17308267
    [Abstract] [Full Text] [Related]

  • 16. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer.
    McArthur HL, Mahoney KM, Morris PG, Patil S, Jacks LM, Howard J, Norton L, Hudis CA.
    Cancer; 2011 Dec 15; 117(24):5461-8. PubMed ID: 21681735
    [Abstract] [Full Text] [Related]

  • 17. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
    Arslan UY, Turker I, Aksoy S, Oksuzoglu B, Helvaci K, Yildirim Ozdemir N, Uyeturk U, Uysal Sonmez O, Budakoglu B, Zengin N.
    J BUON; 2013 Dec 15; 18(3):585-93. PubMed ID: 24065468
    [Abstract] [Full Text] [Related]

  • 18. Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.
    Loi S, Dafni U, Karlis D, Polydoropoulou V, Young BM, Willis S, Long B, de Azambuja E, Sotiriou C, Viale G, Rüschoff J, Piccart MJ, Dowsett M, Michiels S, Leyland-Jones B.
    JAMA Oncol; 2016 Aug 01; 2(8):1040-7. PubMed ID: 27100299
    [Abstract] [Full Text] [Related]

  • 19. Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial.
    Metzger-Filho O, Procter M, de Azambuja E, Leyland-Jones B, Gelber RD, Dowsett M, Loi S, Saini KS, Cameron D, Untch M, Smith I, Gianni L, Baselga J, Jackisch C, Bell R, Sotiriou C, Viale G, Piccart-Gebhart M.
    J Clin Oncol; 2013 Jun 01; 31(16):1954-60. PubMed ID: 23589556
    [Abstract] [Full Text] [Related]

  • 20. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
    Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, Utriainen T, Turpeenniemi-Hujanen T, Jyrkkiö S, Möykkynen K, Helle L, Ingalsuo S, Pajunen M, Huusko M, Salminen T, Auvinen P, Leinonen H, Leinonen M, Isola J, Kellokumpu-Lehtinen PL.
    J Clin Oncol; 2009 Dec 01; 27(34):5685-92. PubMed ID: 19884557
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.